2018 AANS Annual Scientific Meeting-Glioblastoma comprises of two molecularly distinct immunological signatures

Glioblastoma comprises of two molecularly distinct immunological signatures

Video Transcription

Video Summary

Dr. Matthew Pease, a neurosurgery resident at the University of Pittsburgh Medical Center, presented research on glioblastoma, the most common and lethal primary malignant brain tumor. He discussed the limited success of traditional chemotherapy and radiation treatments due to the tumor's heterogeneity and explored the use of immunotherapy. Dr. Pease and his team analyzed gene expression data from 509 glioblastomas and identified two distinct subgroups based on immune-related genes. They compared their findings to existing classification systems and found that their system may be superior in identifying immune-rich tumors. Additionally, they identified potential targets for immunotherapies, such as Nivolumab, which could guide future clinical trials. This research was supported by a grant from the Research Update in Neuroscience for Neurosurgeons.

Asset Caption

Matthew W. Pease, MD

Keywords

glioblastoma

immunotherapy

gene expression data

immune-related genes

Nivolumab